SYMBOL: NASDAQ:FATE | DIRECTION: LONG | TIMEFRAME: Weekly
Published: August 2026

Right.

Fate Therapeutics has gone from one hundred and twenty dollars to 80 cents. That is extraordinary. The share price has been murdered. Absolutely demolished. We are talking about a small cap biotech that lost ninety-seven percent of its value, and yet here we stand, looking at a chart that suggests the cremation might be over.

The thing about catastrophic drawdowns is that they occasionally mark the end of a story rather than a continuation. This one has the fingerprints all over it. Volume is drying up on the way down while the daily chart is in a uptrend structure. Higher highs and higher lows. That is not noise.

And yet.

The crowd sees a dead company with a dead chart as financial wizards chase AI Tech and shiny metals. They see ninety-nine percent drops and assume another ninety-nine percent is coming. They're probably wrong, which is why we are here.

On the above 3 week chart Fate Therapeutics Inc has bounced sharply from the wreckage and is now trading at the eighty-sixth percentile of its fifty-two week range. Four reasons now exist to expect a serious retest of prior resistance and potentially a run toward the all time high of 120. They include:

1) Five-year channel breakout, confirmed. The descending channel from the 2021 highs has contained every rally attempt for five years. Price has now broken above it and held.

2) Phase 2 registrational trial with FDA fast-track status attached. FT819 has RMAT designation. It has also been selected into the FDA’s CDRP programme, which is described as “highly selective” and which almost nobody has heard of, including, apparently, the people pricing this stock. RECLAIM-LN, a potentially registrational Phase 2 trial in lupus nephritis, begins dosing in the second half of 2026. That is this year. That is in the next few months.

3) Clinical responses without chemotherapy. Three out of three. In Regimen B of the Phase 1 study, three of three lupus patients achieved SRI-4 response and two of three reached low disease activity state, with no conditioning chemotherapy at all. For context, most CAR T-cell trials require up to three days of cyclophosphamide and fludarabine beforehand, which patients find about as pleasant as it sounds. Fate is producing responses without it. Small sample, early data, yes. Still three out of three. Twenty-seven patients treated to date, eight of them as outpatients. An off-the-shelf cell therapy you can receive without chemotherapy and go home afterwards is not an incremental improvement. It is a different product category.

4) Over 500 issued patents. And they cut costs 20%. The iPSC platform is protected by more than 500 issued patents and 500 pending applications. Meanwhile operating expenses fell 20% year on year in Q1 2026, which extended the runway into 2028. A biotech that reduces spending while accelerating its lead programme into registrational trials is not a company in trouble. It is a company being run properly. The market has not adjusted its opinion accordingly. It rarely does until something forces it to.

Now the honest bit
This is clinical-stage biotech. FATE loses approximately $31 million a quarter and has no approved product. The sample sizes are small. Phase 1 data becomes Phase 2 disappointment with some regularity in this sector. Cell therapy is difficult, expensive, and littered with companies that had promising early data and nothing else. Price has also already tripled from the lows near $0.96, so the easy part of this move is behind us. If RECLAIM-LN fails, this thesis fails with it, completely and without argument. Position size accordingly, and by that I mean properly, not the way you normally do it.


The crowd
Everybody left. Fate traded above $100 in 2021 during the cell therapy enthusiasm, then a partnership collapsed, the sector fell apart, and retail investors have spent five years watching it decline. They are not coming back to look at the pipeline. Institutional biotech money moved to obesity drugs, because that is where the returns were and fund managers are not paid to be interesting.
So the company sat there with its 500 patents, its $175 million, its FDA designations, and its three-out-of-three responses, at a valuation that implied the science was worth roughly nothing. Everyone stopped watching at exactly the point the data started working. Then the chart broke out of a five-year channel and still nobody looked.
 
Could this go to zero? It is biotech. Obviously it could. I am not going to sit here and pretend otherwise. But a debt-free company with a registrational trial, RMAT designation, a thousand patents and a confirmed five-year channel breakout is currently valued at barely more than its bank balance. One of those things is mis-priced. I have a view on which.

Good luck.
Ww
 
Type: Speculative fundamental long / clinical-stage biotech  |  Timeframe: 12–24 months
 




===================================================
Disclaimer: This idea is for educational and informational purposes only. It is not financial advice. Fate Therapeutics is a clinical-stage biopharmaceutical company with no approved products and no product revenue. It is currently loss-making. Clinical trial results are inherently uncertain, and early-phase data frequently fails to replicate in later-stage trials. Clinical-stage biotech investments carry a risk of total capital loss. Trial failures, regulatory setbacks, or the need to raise additional capital may result in substantial or complete loss of investment. Financial figures are taken from the Company’s Q1 2026 results published 13 May 2026 and predate the Q2 2026 results scheduled for 11 August 2026. Always do your own research and consult a qualified financial adviser before making any investment decisions. Past performance is not indicative of future results.